Northwest Biotherapeutics (NWBO) Target Lifted to $15.10 at Summer Street
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Northwest Biotherapeutics (NWBO) Refutes Adam Feuerstein's Claims
March 12, 2014 10:15 AM EDTNorthwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted false statements and material distortions made by Adam Feuerstein in an article on Tuesday, March 11.
Feuerstein falsely accused NW Bio of manipulating its news by delaying announcement of the Hospital Exemption approval by the Paul Ehrlich Institute ("PEI," the FDA of Germany). Feuerstein's accusations were factually wrong, materially misleading and reflect a lack of knowledge on... More
Oppenheimer Downgrades Northwest Biotherapeutics (NWBO) to Perform
March 12, 2014 7:35 AM EDTOppenheimer downgraded Northwest Biotherapeutics (NASDAQ: NWBO) from Outperform to Perform and removed its price target (prior $5.00).
For an analyst ratings summary and ratings history on Northwest Biotherapeutics click here. For more ratings news on Northwest... More
Northwest Biotherapeutics (NWBO) Receives 'Very Strong' Endorsement, Summer Street Says
March 10, 2014 1:22 PM EDTSummer Street analyst Carol Werther maintained a Buy rating and $10.33 price target on Northwest Biotherapeutics (NASDAQ: NWBO) after the company announced this morning that Germany has approved DCVax-L, its Glioblastoma multiforme (GBM) vaccine, for an early access program. The analyst notes this allows... More
Northwest Biotherapeutics (NWBO) Said GBM Brain Cancer Trial Recommend To Continue
March 7, 2014 8:12 AM ESTNorthwest Biotherapeutics (NASDAQ: NWBO) is moving up 8% in pre-open trade after the company announced today, in response to shareholder inquiries, that the Data Safety Monitoring Board (DSMB) has made an unblinded review of the safety data for the Company's ongoing international Phase III... More
